Expert Perspectives on Novel Combination Therapy in Newly Diagnosed Myeloma

home / between-the-lines / expert-perspectives-on-novel-combination-therapy-in-newly-diagnosed-myeloma

Panelists discuss how emerging data and guidelines reinforce quadruplet therapy as the foundation of NDMM treatment, supported by the ADVANCE trial’s findings on efficacy, safety, and applicability across risk groups. They highlight how precision testing, risk assessment, and evolving biologic therapies continue to refine individualized patient care.

2 experts are featured in this series.

EP. 1: Review of Latest Guidelines on Quad Therapy in NDMM

C. Ola Landgren, MD, PhD;Noopur Raje, MD
October 27th 2025

Panelists discuss how quadruplet therapy has become the new benchmark for NDMM, offering deeper and more durable responses than previous triplet regimens.

2 experts are featured in this series.

EP. 2: Classifying High-Risk Patients With NDMM

C. Ola Landgren, MD, PhD;Noopur Raje, MD
October 27th 2025

Panelists discuss how risk stratification using cytogenetic and molecular markers is vital to tailoring NDMM therapy and improving long-term outcomes.